Types of seasonal influenza vaccineArchived

Data set

A detailed overview of available seasonal influenza vaccines in the EU/EEA will not be available for the 2020/21 vaccination programmes, due to limited ECDC resources following the COVID-19 response.

 

Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers. The inactivated influenza vaccines available in the EU/EEA may contain either split virion influenza virus products or subunit influenza products. Adjuvanted inactivated subunit influenza vaccines for older people are available in some EU/EEA Member States.

Injected quadrivalent inactivated influenza vaccines, available from the 2014/2015 season in some EU/EEA countries, are expected to replace the trivalent vaccines over time. Although available in the private market in some European countries, vaccine authorisation, vaccine availability, observed vaccine effectiveness and the cost may influence the speed of this replacement.

In 2011, a live attenuated influenza vaccine (LAIV) for intranasal use was approved in the EU/EEA for children and adolescents (2-17 years of age). All live attenuated influenza vaccines currently available are quadrivalent combination vaccines containing two influenza A strains (H1N1 and H3N2 subtypes) and two influenza B strains (Victoria and Yamagata lineages) as per WHO recommendations.

The universal paediatric programmes organised in Finland and the United Kingdom offer quadrivalent LAIV to either young children 2-3 or 2-11 years of age, respectively.

Since seasonal influenza vaccines are usually recommended for several vulnerable populations who are poorer immune responders due to age or disease, several attempts to improve the vaccines have been explored over the last 10-15 years such as: increasing the antigen dose administered, intradermal administration to activate other arms of the immune system, and adding immunostimulating compounds such as adjuvants (See reference 1-4).

Products utilising these new techniques are now authorised and available in some EU/EEA countries. See table below. For human influenza vaccines, MF59 (squalene) and AS03 (squalene and α-tocopherol) have been approved as adjuvants by regulatory agencies in the EU, Canada and the United States. Data from several observational studies indicating improved performance and reductions in hospitalisations in older adults against influenza disease and hospitalisations have been included in the label for the adjuvanted trivalent influenza vaccine.

Most influenza vaccines, both inactivated and live attenuated, are based on production of influenza viruses/antigens in fertilised hens' eggs. These vaccines can therefore not be given to egg-allergic individuals developing severe symptoms upon exposure to egg proteins. Hence, a few manufacturers have developed cell-based influenza vaccines which can be given to severely egg-allergic individuals. Use of cell-based products may have an improved match to circulating influenza strains as they avoid egg-adaption issues. 

Overview of available seasonal influenza vaccines in the EU/EEA (2019/20 season)

Name of product Manufacturer Vaccine type Adjuvant Administration route Produced in  Age recommended
3Fluart Fluart Innovative Vaccines Kft Inactivated Aluminium phosphate gel Intramuscular Egg From 3 years 
Afluria Pfizer/Seqirus  Inactivated None Intramuscular Egg From 5 years
Agrippal Seqirus  Inactivated/ subunit None Intramuscular Egg From 6 months
Fluad Seqirus  Inactivated/ subunit Squalene (MF59) intramuscular Egg From 65 years
Fluarix  GlaxoSmithKline  Inactivated/ split None  intramuscular/ subcutaneous Egg From 6 months
Fluarix Tetra GlaxoSmithKline  Inactivated/ split None intramuscular Egg From 6 months
Flucelvax Tetra Seqirus  Inactivated None intramuscular Cell From 9 years
Fluenz Tetra AstraZeneca  Live attenuated None intranasal Egg From 24 months to 17 years
Imuvac Abbot Biologicals/Mylan Products Ltd. (Marketing Authorisation Holder) Inactivated None intramuscular Egg From 6 months
Influvac Xanaflu Mylan Products Ltd.  Inactivated None intramuscular Egg From 6 months
Influvac Tetra Mylan Products Ltd.  Inactivated None Intramuscular/ subcutaneous   Egg From 3 years
Trivalent Influenza Vaccine High Dose Sanofi Pasteur split virion, inactivated None intramuscular Egg From 65 years
Vaxigrip Istivac Mutagrip Sanofi Pasteur Inactivated None Intramuscular/ subcutaneous   Egg From 6 months
Vaxigrip Tetra Sanofi Pasteur Inactivated None Intramuscular/ subcutaneous   Egg From 6 months
Xanaflu Tetra Fluvaccinol Subunit Tetra Batrevac Tetra Influenza vaccine Tetra MYL Abbot Biologicals/Mylan Products Ltd. (Marketing Authorisation Holder) Inactivated None Intramuscular/ deeply subcutaneous   Egg From 3 years 

* The same product may be sold under different names ** Split virion by Triton X-100 and formaldehyde inactivated *** Beta-propriolactone-inactivated and taurodeoxycholate- split virion vaccine

Source of information: EMA and national regulatory authority websites

References

  1. Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, Mahmud SM. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine. 2017 May 15;35(21):2775-2780. doi: 10.1016/j.vaccine.2017.03.092. Epub 2017 Apr 18.
  2. Marra F, Young F, Richardson K, Marra CA. A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respir Viruses. 2013 Jul;7(4):584-603. doi: 10.1111/irv.12000. Epub 2012 Sep 13.
  3. Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2017 Jan 23;35(4):513-520. doi: 10.1016/j.vaccine.2016.12.011.
  4. Chada KE, Forshee R, Golding H, Anderson S, Yang H. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines. Vaccine. 2017 May 31;35(24):3162-3170. doi: 10.1016/j.vaccine.2017.04.029. Epub 2017 May 5.
  5. Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden M, Ramler G, Bigham M. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013 Dec 9;31(51):6122-8. doi: 10.1016/j.vaccine.2013.07.059. Epub 2013 Aug 6.

Availability of influenza vaccines by country in EU/EEA in the 2019/20 season

Download table:

Data

Availability of influenza vaccines by country in EU/EEA in the 2019/20 season

Data set -

More about this topic

Immunisation and vaccines

Vaccines represent one of the most effective and cost-saving public health intervention.

Vaccine-preventable diseases

Find out more about the diseases that vaccines prevent: latest updates, current and past disease threats and outbreaks, surveillance and disease data, preventive measures and basic disease facts.

All updates on influenza vaccination

Data

Poster: Influenza during the COVID-19 pandemic - why it's important to get vaccinated against influenza

Poster -

Event

Flu Awareness Week, 5-9 October 2020

5 Oct 2020 - 9 Oct 2020

Data

Poster: Influenza during the COVID-19 pandemic - protect yourself and others from COVID-19 during influenza vaccination

Poster -

News

Looking at newer enhanced seasonal influenza vaccines: a systematic review of efficacy, effectiveness and safety

News story -

Publication

Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines

Technical report -